50.52

2.62% 1.29

Akero Therapeutics Inc (AKRO)

Overview News Price History Option Chain Financials Why AKRO Down? Discussions Forecast

Akero Therapeutics Inc stock is traded at $50.52, with a volume of 840.26K. It is up +2.62% in the last 24 hours and up +131.00% over the past month. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Previous Close:

$49.23

Open:

$49.24

24h Volume:

840.26K

Relative Volume:

0.74

Market Cap:

$3.85B

Revenue:

Net Income/Loss:

$-237.22M

P/E Ratio:

-13.37

EPS:

-3.78

Net Cash Flow:

$-212.64M

1W Performance:

-6.81%

1M Performance:

+131.00%

6M Performance:

+112.63%

1Y Performance:

+132.28%

1-Day Range:

$49.24

$51.40

1-Week Range:

$48.57

$55.81

52-Week Range:

$17.86

$58.40

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name

Akero Therapeutics Inc

Sector

Healthcare (1173)

Industry

Biotechnology (677)

Phone

650-487-6488

Address

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Employee

Twitter

@akerotx

Next Earnings Date

2024-11-11

Latest SEC Filings

AKRO's Discussions on Twitter

Compare AKRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKRO Akero Therapeutics Inc	50.52	3.85B	0	-237.22M	-212.64M	-3.78
VRTX Vertex Pharmaceuticals Inc	459.00	117.92B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	673.60	73.64B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	639.41	38.85B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	256.45	33.20B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	119.83	28.73B	3.30B	-501.07M	1.03B	-2.1146

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-25	Upgrade	BofA Securities	Neutral → Buy
Jan-27-25	Reiterated	H.C. Wainwright	Buy
Nov-18-24	Initiated	Citigroup	Buy
Apr-22-24	Resumed	BofA Securities	Neutral
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight
Aug-28-23	Initiated	UBS	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-10-21	Initiated	BofA Securities	Buy
Feb-26-21	Initiated	Guggenheim	Buy
Sep-10-20	Initiated	Morgan Stanley	Overweight
Jul-20-20	Reiterated	H.C. Wainwright	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy
Jul-01-20	Reiterated	H.C. Wainwright	Buy
Mar-02-20	Initiated	H.C. Wainwright	Buy
Feb-10-20	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Evercore ISI	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight
Jul-15-19	Initiated	Jefferies	Buy
Jul-15-19	Initiated	ROTH Capital	Buy

View All

Akero Therapeutics Inc Stock (AKRO) Latest News

02:15 AM

Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Large Increase in Short Interest - Defense World

02:15 AM

01:33 AM

Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Target Price at $75.86 - Defense World

01:33 AM

Feb 16, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Feb 16, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 30,000 Shares - MarketBeat

Feb 16, 2025

Feb 15, 2025

(AKRO) Technical Pivots with Risk Controls - Stock Traders Daily

Feb 15, 2025

Feb 13, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect - Markets Insider

Feb 13, 2025

Is Akero Therapeutics Inc (NASDAQ: AKRO) A Good Pick For New Investors Now? - Stocks Register

Feb 13, 2025

Feb 12, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by abrdn plc - MarketBeat

Feb 12, 2025

Akero Therapeutics director Graham Walmsley acquires $9.6 million in stock - MSN

Feb 12, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out - Markets Insider

Feb 12, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 18,750 Shares - MarketBeat

Feb 12, 2025

Akero Therapeutics Insider Sold Shares Worth $1,581,994, According to a Recent SEC Filing - Marketscreener.com

Feb 12, 2025

Feb 11, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Director G. Walmsley Graham Acquires 200,000 Shares - MarketBeat

Feb 11, 2025

Akero Therapeutics CEO Cheng Andrew Sells 30,000 Shares - TradingView

Feb 11, 2025

Investigation announced for Long-Term Investors in shares - openPR

Feb 11, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation - Markets Insider

Feb 11, 2025

Financial Analysis: Akero Therapeutics Inc (AKRO)’s Ratios Unveil Key Insights - The Dwinnex

Feb 11, 2025

Feb 10, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation - Markets Insider

Feb 10, 2025

Akero Therapeutics' chief scientific officer sells $1.06 million in stock - MSN

Feb 10, 2025

Feb 09, 2025